In vitro comprehensive phosphoproteomic and immunoblotting analyses performed to analyze the mechanism of the anti-tumor effect on ABC-DLBCL suggested that tirabrutinib exerts its effect in both TMD8 and U-2932 cells by downregulating the phosphorylation signal of ERK and NF-κB signaling, which have been reported as downstream signals of BTK [63,64]. The gene discussed is MAPK1; the disease is diffuse large B-cell lymphoma.